Mangin Dee, Bahat Gülistan, Golomb Beatrice A, Mallery Laurie Herzig, Moorhouse Paige, Onder Graziano, Petrovic Mirko, Garfinkel Doron
Department of Family Medicine, Faculty of Health Sciences, McMaster University, 100 Main Street West, Hamilton, ON, Canada.
Department of General Practice, University of Otago, Christchurch, New Zealand.
Drugs Aging. 2018 Jul;35(7):575-587. doi: 10.1007/s40266-018-0554-2.
Globally, the number of drug prescriptions is increasing causing more adverse drug events, which is now a significant cause of mortality, morbidity, and disability that has reached epidemic proportions. The risk of adverse drug events is correlated to very old age, multiple co-morbidities, dementia, frailty, and limited life expectancy, with the major contributor being polypharmacy. Each characteristic alters the risk-benefit balance of medications, typically reducing anticipated benefits and amplifying risk. Current clinical guidelines are based on evidence proven in younger/healthier adult populations using a single disease model and their application to older adults with multimorbidity, in whom testing has not been conducted, yields a different risk-benefit prospect and makes inappropriate medication use and polypharmacy inevitable. Applying inappropriate clinical practice guidelines to older adults is antithetical to good healthcare, is likely to increase health inequity, and is associated with substantial negative clinical, economic, and social implications for health systems. The casualties are on the scale of a war or epidemic, yet are usually invisible in measures of healthcare quality and formal recommendations. Radical and rapid action is required to achieve a better quality of life for older populations and to remain true to the principles of medical professionalism and evidence-based medicine that place patients' interests and autonomy at the fore. This first International Group for Reducing Inappropriate Medication Use & Polypharmacy position statement briefly details the causes, consequences, and extent of inappropriate medication use and polypharmacy. This article outlines current strategies to reduce inappropriate medication use, provides evidence for their effect, and then proposes recommendations for moving forward with 10 recommendations for action and 12 recommendations for research. We conclude that an urgent integrated effort to reduce inappropriate medication use and polypharmacy should be a leading global target of the highest priority. The cornerstone of this position statement from the International Group for Reducing Inappropriate Medication Use & Polypharmacy is the understanding that without evidence of definite relevant benefit, when it comes to prescribing, for many older patients 'less is more'. This approach differs from most other current recommendations and guidance in medical care, as the focus is on what, when, and how to stop, rather than on when to start medications/interventions. Disrupting the framework that indiscriminately applies standard guidelines to older adults requires a new approach that better serves patients with multimorbidity. This transition requires a shift in medical education, research, and diagnostic frameworks, and re-examination of the measures used as quality indicators. In achieving this objective, we promote a return to some of the original concepts of evidence-based medicine: which considers scientific data (where it exists), clinical judgment, patient/family preference, and context. A shift is needed: from the current model that focuses on single conditions to one that simultaneously considers multiple conditions and patient priorities. This approach reframes the clinician's role as a professional providing care, rather than a disease technician.
在全球范围内,药物处方数量不断增加,导致更多药物不良事件,这已成为死亡率、发病率和残疾的一个重要原因,且已达到流行程度。药物不良事件的风险与高龄、多种合并症、痴呆、虚弱以及预期寿命有限相关,其中主要因素是多重用药。每种特征都会改变药物的风险效益平衡,通常会降低预期效益并放大风险。当前的临床指南基于在年轻/健康成年人群中经证据证明的单一疾病模型,将其应用于未进行过测试的患有多种合并症的老年人时,会产生不同的风险效益前景,并不可避免地导致用药不当和多重用药。将不适当的临床实践指南应用于老年人与优质医疗背道而驰,可能会加剧健康不平等,并对卫生系统产生重大的负面临床、经济和社会影响。这些伤亡规模如同战争或流行病,但在医疗质量衡量标准和正式建议中通常难以察觉。需要采取激进和迅速的行动,以提高老年人群的生活质量,并坚持将患者利益和自主权置于首位的医学专业精神和循证医学原则。这份由减少用药不当和多重用药国际小组发布的首份立场声明简要详述了用药不当和多重用药的原因、后果及程度。本文概述了减少用药不当的当前策略,提供了其效果的证据,然后提出了推进措施,包含10项行动建议和12项研究建议。我们得出结论,迫切需要开展综合努力以减少用药不当和多重用药,这应成为全球首要的最高优先目标。减少用药不当和多重用药国际小组这份立场声明的基石是,认识到在开药时,对于许多老年患者而言,若无明确相关益处的证据,“少即是多”。这种方法与当前医疗保健中的大多数其他建议和指导不同,因为重点在于停止用药的内容、时间和方式,而非开始用药/干预的时间。打破不加区分地将标准指南应用于老年人的框架需要一种新方法,以更好地服务患有多种合并症的患者。这种转变需要医学教育、研究和诊断框架的转变,以及对用作质量指标的措施进行重新审视。为实现这一目标,我们倡导回归循证医学的一些原始概念:即考虑科学数据(若有)、临床判断、患者/家庭偏好和背景。需要转变:从当前专注单一病症的模式转变为同时考虑多种病症和患者优先事项的模式。这种方法将临床医生的角色重新界定为提供护理的专业人员,而非疾病技术员。